Skip to main content
NVDA-2.10%AAPL+2.69%GOOGL+0.24%MSFT+0.56%AMZN+0.12%TSM-0.81%SPCX+2.02%AVGO+0.03%META-0.22%TSLA-0.47%SKHY-3.57%MU-4.31%BRK-B-0.24%LLY+0.25%JPM-0.60%WMT+0.20%AMD-2.67%V-0.09%XOM+0.78%ASMLa-1.66%JNJ-0.19%INTC-4.47%MA-0.42%0700.HK-1.94%1398.HK+0.79%ORCL-2.97%ABBV+0.61%BAC-0.65%CSCO-0.91%CVX0.00%COST-0.01%KO+0.78%LRCX-4.62%CAT-1.46%AP2d-1.55%0005.HK-0.78%AMAT-2.16%UNH-0.23%HSBA.L-1.30%DELL-3.64%PG-0.05%MS-0.60%GE-0.47%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.05%HD-1.35%0939.HK+1.66%GS-0.76%NZDJPY-2.49%AUDJPY-1.75%CHFJPY-1.55%NZDCAD-1.40%EURNZD+1.34%GBPNZD+1.32%USDJPY-1.27%NZDUSD-1.25%EURJPY-1.20%GBPJPY-1.18%CADJPY-1.10%NZDCHF-0.97%USDZAR+0.89%USDNOK+0.82%EURZAR+0.79%USDSEK+0.77%AUDNZD+0.77%GBPZAR+0.74%EURNOK+0.72%AUDCAD-0.68%EURSEK+0.67%AUDDKK-0.60%CHFNOK+0.59%EURAUD+0.56%GBPAUD+0.55%USDTHB+0.54%CHFSEK+0.53%AUDUSD-0.49%AUDSGD-0.48%CADCHF+0.43%USDMXN+0.43%GBPTRY+0.41%NOKJPY-0.35%USDPLN+0.35%GBPCHF+0.35%EURCHF+0.34%GBPHKD+0.32%NZDSGD-0.31%USDCHF+0.29%GBPMXN-0.28%SGDJPY+0.25%EURPLN+0.25%USDSGD+0.21%AUDCHF-0.21%USDILS+0.16%USDCAD-0.15%AUDNOK+0.12%NZDMXN-0.12%PLNJPY+0.12%EURSGD+0.11%EURHKD-0.11%USDTRY+0.11%GBPCAD-0.10%USDDKK+0.10%EURCAD-0.10%EURCZK-0.08%USDCNH+0.08%GBPUSD+0.08%EURUSD+0.06%GBPSGD+0.06%USDCOP-0.04%CHFSGD-0.02%USDHKD+0.01%EURGBP+0.01%EURDKK0.00%EURCNH0.00%XPTUSD-5.22%UKOIL+4.94%USOIL+4.58%HG1-4.54%GAGUSD-4.20%XAGUSD-4.20%GAUUSD-0.80%XAUUSD-0.80%COTTON+0.67%S1+0.49%XNGUSD+0.48%COFFEE-0.46%BTCUSD-1.38%ETHUSD-0.57%USDTUSD-0.02%XRPUSD-2.75%SOLUSD-1.67%TRXUSDT+0.03%ZECUSDT-8.60%DOGEUSD-2.91%XMRUSDT-0.86%LINKUSD-1.49%XLMUSD-1.82%BCHUSDT-9.83%LTCUSD-1.56%UNIUSD-2.61%TONUSD+24.88%HBARUSDT-2.10%SUIUSD-3.76%TAOUSDT-4.65%AAVEUSD-2.57%DOTUSDT-2.67%ICPUSDT-1.78%ONDOUSDT-3.23%WLDUSDT-2.67%ATOMUSDT-3.51%ARBUSDT-0.87%JUPUSDT-4.25%INJUSDT-3.68%STXUSDT-4.16%FETUSDT-3.86%TIAUSDT-1.65%PYTHUSDT-1.33%SEIUSDT-6.02%IMXUSDT-3.85%GRTUSDT-3.02%WIFUSDT-5.38%OPUSDT-3.00%POLUSDT-4.56%IOTAUSDT-3.87%AXSUSDT-2.36%FARTCOINUSDT-4.03%EOSUSDT-2.91%DYDXUSDT-2.49%ORDIUSDT-1.37%GALAUSDT-3.65%NOTUSDT-2.97%RONINUSDT-2.64%NVDA-2.10%AAPL+2.69%GOOGL+0.24%MSFT+0.56%AMZN+0.12%TSM-0.81%SPCX+2.02%AVGO+0.03%META-0.22%TSLA-0.47%SKHY-3.57%MU-4.31%BRK-B-0.24%LLY+0.25%JPM-0.60%WMT+0.20%AMD-2.67%V-0.09%XOM+0.78%ASMLa-1.66%JNJ-0.19%INTC-4.47%MA-0.42%0700.HK-1.94%1398.HK+0.79%ORCL-2.97%ABBV+0.61%BAC-0.65%CSCO-0.91%CVX0.00%COST-0.01%KO+0.78%LRCX-4.62%CAT-1.46%AP2d-1.55%0005.HK-0.78%AMAT-2.16%UNH-0.23%HSBA.L-1.30%DELL-3.64%PG-0.05%MS-0.60%GE-0.47%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.05%HD-1.35%0939.HK+1.66%GS-0.76%NZDJPY-2.49%AUDJPY-1.75%CHFJPY-1.55%NZDCAD-1.40%EURNZD+1.34%GBPNZD+1.32%USDJPY-1.27%NZDUSD-1.25%EURJPY-1.20%GBPJPY-1.18%CADJPY-1.10%NZDCHF-0.97%USDZAR+0.89%USDNOK+0.82%EURZAR+0.79%USDSEK+0.77%AUDNZD+0.77%GBPZAR+0.74%EURNOK+0.72%AUDCAD-0.68%EURSEK+0.67%AUDDKK-0.60%CHFNOK+0.59%EURAUD+0.56%GBPAUD+0.55%USDTHB+0.54%CHFSEK+0.53%AUDUSD-0.49%AUDSGD-0.48%CADCHF+0.43%USDMXN+0.43%GBPTRY+0.41%NOKJPY-0.35%USDPLN+0.35%GBPCHF+0.35%EURCHF+0.34%GBPHKD+0.32%NZDSGD-0.31%USDCHF+0.29%GBPMXN-0.28%SGDJPY+0.25%EURPLN+0.25%USDSGD+0.21%AUDCHF-0.21%USDILS+0.16%USDCAD-0.15%AUDNOK+0.12%NZDMXN-0.12%PLNJPY+0.12%EURSGD+0.11%EURHKD-0.11%USDTRY+0.11%GBPCAD-0.10%USDDKK+0.10%EURCAD-0.10%EURCZK-0.08%USDCNH+0.08%GBPUSD+0.08%EURUSD+0.06%GBPSGD+0.06%USDCOP-0.04%CHFSGD-0.02%USDHKD+0.01%EURGBP+0.01%EURDKK0.00%EURCNH0.00%XPTUSD-5.22%UKOIL+4.94%USOIL+4.58%HG1-4.54%GAGUSD-4.20%XAGUSD-4.20%GAUUSD-0.80%XAUUSD-0.80%COTTON+0.67%S1+0.49%XNGUSD+0.48%COFFEE-0.46%BTCUSD-1.38%ETHUSD-0.57%USDTUSD-0.02%XRPUSD-2.75%SOLUSD-1.67%TRXUSDT+0.03%ZECUSDT-8.60%DOGEUSD-2.91%XMRUSDT-0.86%LINKUSD-1.49%XLMUSD-1.82%BCHUSDT-9.83%LTCUSD-1.56%UNIUSD-2.61%TONUSD+24.88%HBARUSDT-2.10%SUIUSD-3.76%TAOUSDT-4.65%AAVEUSD-2.57%DOTUSDT-2.67%ICPUSDT-1.78%ONDOUSDT-3.23%WLDUSDT-2.67%ATOMUSDT-3.51%ARBUSDT-0.87%JUPUSDT-4.25%INJUSDT-3.68%STXUSDT-4.16%FETUSDT-3.86%TIAUSDT-1.65%PYTHUSDT-1.33%SEIUSDT-6.02%IMXUSDT-3.85%GRTUSDT-3.02%WIFUSDT-5.38%OPUSDT-3.00%POLUSDT-4.56%IOTAUSDT-3.87%AXSUSDT-2.36%FARTCOINUSDT-4.03%EOSUSDT-2.91%DYDXUSDT-2.49%ORDIUSDT-1.37%GALAUSDT-3.65%NOTUSDT-2.97%RONINUSDT-2.64%
TB

Theravance Biopharma Inc (TBPH)

NASDAQ • Healthcare

$17.05
+$0 (+0.0%)
Market open

Last close at September 9, 2026 at 20:00 UTC

Open$17.07
Previous Close$17.06
Day Range$17.05 - $17.08
Avg. Volume (3M)382.8K
Market Cap$882.6M
P/E Ratio16.1
52 Week Range
$13.08$21.03
Next EarningsIn 61 daysNov 10, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$20.7M100%
Gross Profitminus cost of goods$19.2M93%

In plain terms: out of every $100 in revenue, Theravance Biopharma Inc currently loses $28.

Fundamentals & Financials

Revenue (TTM)
$104.3M
Net Income (TTM)
$53.8M
EPS (TTM)
$1.06
ROA (TTM)
11.45%
Current Ratio
13.54

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-86.4%Q1 2026$0.06
-443.6%Q2 2026-$0.1
-251.7%Q3 2026-$0.11
Next

Nov 10

in 61 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -251.7%

Theravance Biopharma’s second fiscal quarter of 2026 results trailed consensus on revenue, based on preliminary figures reported August 10, 2026. Revenue fell 20.9% year over year to about $20.7 million (down from $26.2 million a year ago), and it trailed expectations with revenue of $20.7 million versus the $22.5 million estimate (-8%). The business is driven by its respiratory franchise led by YUPELRI in the U.S. On cash generation, the company posted negative operating cash flow of roughly $8.9 million for the quarter. Consensus for the next period calls for EPS of $0.24 on revenue of $22.0 million.

View full earnings history

About Theravance Biopharma Inc

Theravance Biopharma Inc is a NASDAQ-listed biotechnology company focused on respiratory and other specialty medicines in the United States. FY2025 revenue was $107.5 million. Its marketed product is YUPELRI, a once-daily nebulized long-acting muscarinic antagonist for COPD, while Ampreloxetine remains an investigational once-daily norepinephrine reuptake inhibitor.

Name
Theravance Biopharma Inc
CEO
Rick E. Winningham
Website
www.theravance.com
Industry
Healthcare
Year Founded
2013
Employees
90

Today's Snapshot

AI-generated

So far today, TBPH is trading slightly lower at 17.03, in line with a flat sector. Theravance Biopharma issued merger-related disclosures involving Zymeworks, a biotech company.

Trading Volume

Below 10d avg (380.8K)

106.6K

vs S&P 500 Today

Moderate Outperformance

+0.41%

Updated: September 10, 2026 at 16:50 UTC

Technical Indicators

4 Buy3 Neutral1 Sell
TBPH shows constructive technicals with a clear trend backdrop: ADX is strong, indicating directional strength, and on-balance-volume is positive, supporting the buy bias. Momentum readings are neutral to mildly supportive—RSI sits in the mid-50s and MACD is near flat—while the stock trades around its short-term averages and sits above most medium-term moving averages, though slightly beneath the 200-day pivot near $17.06. Volatility is low with a tight ATR, which points to orderly price action. This combination supports the buy stance. Technical takeaway: Buy.
All signals
  • EMA (5 indicators)$16.81 - $17.05
    Buy
  • RSI (14)55.39
    Neutral
  • Stochastic %K (14, 3, 3)31.43
    Neutral
  • MACD Level (12, 26)0.04
    Neutral

Peers & Related Assets

VIRVir Biotechnology, Inc.
$10.81-3.3%
AVBPArriVent BioPharma, Inc.
$29.79-1.6%
TYRATyra Biosciences, Inc.
$22.01-17.7%
GLUEMonte Rosa Therapeutics, Inc.
$14.26-0.1%
REPLReplimune Group, Inc.
$14.45-2.2%
GERNGeron Corporation
$1.4-7.3%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.